|

ETX-19477 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • 858 Therapeutics, Inc.1

Indications

  • Castrate Resistant Prostate Cancer1
  • ER+ Breast Cancer1
  • Advanced or Metastatic Solid Tumors1
  • BRCA Mutation1
  • BRCA2 Mutation1

Phoenix, Arizona1 trial

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

Mayo Clinic

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.